Education
About Us
Working with TipRanks
Follow Us
Revive Therapeutics Ltd (TSE:RVV)
:RVV
RESEARCH TOOLSreports
Total Valuation
Revive Therapeutics has a market cap or net worth of C$10.46M. The enterprise value is C$13.40M.
Market CapC$10.46M
Enterprise ValueC$13.40M
Share Statistics
Revive Therapeutics has 418,564,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding418,564,270
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Revive Therapeutics’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -26.47%.
Return on Equity (ROE)-0.78
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-26.47%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee0.00
Profits Per Employee-2.81M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Revive Therapeutics is -0.68. Revive Therapeutics’s PEG ratio is 0.04.
PE Ratio-0.68
PS Ratio0.00
PB Ratio1.43
Price to Fair Value0.53
Price to FCF-2.53
Price to Operating Cash Flow-2.53
PEG Ratio0.04
Income Statement
In the last 12 months, Revive Therapeutics had revenue of 0.00 and earned -5.62M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-328.00
Operating Income-3.29M
Pretax Income-5.62M
Net Income-5.62M
EBITDA-5.60M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -2.60M and capital expenditures 4.00, giving a free cash flow of -2.60M billion.
Operating Cash Flow-2.60M
Free Cash Flow-2.60M
Free Cash Flow per Share>-0.01
Dividends & Yields
Revive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.00
52-Week Price Change0.00%
50-Day Moving Average0.02
200-Day Moving Average0.02
Relative Strength Index (RSI)45.99
Average Volume (3m)134.42K
Important Dates
Revive Therapeutics upcoming earnings date is Oct 27, 2025, TBA Not Confirmed.
Last Earnings DateMay 30, 2025
Next Earnings DateOct 27, 2025
Ex-Dividend Date―
Financial Position
Revive Therapeutics as a current ratio of 0.34, with Debt / Equity ratio of 2.06%
Current Ratio0.34
Quick Ratio0.34
Debt to Market Cap0.00
Net Debt to EBITDA0.14
Interest Coverage Ratio-141.10
Taxes
In the past 12 months, Revive Therapeutics has paid -2.31M in taxes.
Income Tax-2.31M
Effective Tax Rate0.41
Enterprise Valuation
Revive Therapeutics EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.91.
EV to Sales0.00
EV to EBITDA-0.54
EV to Free Cash Flow-0.91
EV to Operating Cash Flow-0.91
Balance Sheet
Revive Therapeutics has C$55.41K in cash and marketable securities with C$0.00 in debt, giving a net cash position of -C$55.41K billion.
Cash & Marketable SecuritiesC$55.41K
Total DebtC$0.00
Net Cash-C$55.41K
Net Cash Per Share>-C$0.01
Tangible Book Value Per Share>-C$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Revive Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-4.84%